ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR plus SOFOSBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3

被引：2
|
作者：
McEwan, P. [1 ,2 ]
Ward, T. [1 ]
Webster, S. [1 ]
Kalsekar, A. [3 ]
Brenner, M. [4 ]
Yuan, Y. [3 ]
机构：
[1] HEOR Ltd, HEOR, Monmouth, S Glam, Wales
[2] Swansea Univ, Sch Human & Hlth Sci, Swansea, W Glam, Wales
[3] Bristol Myers Squibb Co, World Wide Hlth Econ & Outcomes Res, Princeton, NJ USA
[4] Bristol Myers Squibb Pharmaceut Ltd, UK HEOR, Uxbridge, Middx, England
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)31072-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0870
引用
收藏
页码：S666 / S667
页数：2
相关论文
共 50 条
  • [1] ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR plus SOFOSBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3
    McEwan, P.
    Ward, T.
    Webster, S.
    Kalsekar, A.
    Brenner, M.
    Yuan, Y.
    VALUE IN HEALTH, 2015, 18 (03) : A240 - A240
  • [2] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [3] Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
    Phil McEwan
    Samantha Webster
    Thomas Ward
    Michael Brenner
    Anupama Kalsekar
    Yong Yuan
    Cost Effectiveness and Resource Allocation, 15
  • [4] Cost-effectiveness analysis of the use of daclatasvir plus sofosbuvir plus ribavirin (16 weeks and 12 weeks) vs sofosbuvir plus ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy
    Restelli, Umberto
    Alberti, Alfredo
    Lazzarin, Adriano
    Bonfanti, Marzia
    Nappi, Carmela
    Croce, Davide
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (01): : 37 - 44
  • [5] Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients With HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis
    Hezode, Christophe
    Dore, Gregory J.
    Pianko, Stephen
    Pol, Stanislas
    Stuart, Katherine
    Thompson, Alexander
    Tse, Edmund
    Bhore, Rafia
    Jimenez-Exposito, Maria Jesus
    GASTROENTEROLOGY, 2016, 150 (04) : S1096 - S1096
  • [6] DACLATASVIR PLUS SOFOSBUVIR PLUS RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT-EXPERIENCED PATIENTS WITH HCV GENOTYPE 3 INFECTION AND ADVANCED FIBROSIS OR CIRRHOSIS
    Hezode, C.
    Dore, G.
    Pianko, S.
    Pol, S.
    Stuart, K.
    Thompson, A.
    Tse, E.
    Bhore, R.
    Jimenez-Exposito, M. J.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S753 - S754
  • [7] Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
    McEwan, Phil
    Ward, Thomas
    Webster, Samantha
    Yuan, Yong
    Kalsekar, Anupama
    Kamae, Isao
    Kobayashi, Masahiro
    Tang, Ann
    Kumada, Hiromitsu
    HEPATOLOGY RESEARCH, 2016, 46 (05) : 423 - 433
  • [8] SOFOSBUVIR plus PEGINTERFERON/RIBAVIRIN FOR 12 WEEKS VS SOFOSBUVIR plus RIBAVIRIN FOR 16 OR 24 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH GENOTYPE 2 HCV: THE BOSON STUDY
    Foster, G. R.
    Pianko, S.
    Cooper, C.
    Brown, A.
    Forton, D.
    Nahass, R. G.
    George, J.
    Barnes, E.
    Brainard, D. M.
    Massetto, B.
    Lin, M.
    McHutchison, J. G.
    Subramanian, G. M.
    Agarwal, K.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S259 - S260
  • [9] Daclatasvir exposure does not explain lower sustained virologic response rates in cirrhotic patients with HCV genotype 3 following 12 weeks of daclatasvir plus sofosbuvir treatment
    Eley, Timothy
    Wang, Reena
    Huang, Shu-Pang
    Gandhi, Yash
    Cirincione, Brenda
    LaCreta, Frank
    Garimella, Tushar
    HEPATOLOGY, 2015, 62 : 567A - 568A
  • [10] Cost-effectiveness of elbasvir/grazoprevir plus sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina
    Bissio, E.
    Nwankwo, C.
    Corman, S.
    Monsanto, H.
    Montes, J. L.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S189 - S190
12345